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Nephrotic syndrome is a common glomerular disease in children with significant vari-
ability in both incidence and steroid responsiveness among various ethnic groups. The 
average incidence of nephrotic syndrome is 2–16.9 per 100,000 children worldwide. 
Understanding the variability by ethnicity may point to potential factors leading to nephrotic 
syndrome, which remains elusive, and may highlight factors accounting for differences 
in medication response. The emerging role of genetic factors associated with steroid 
responsive and steroid-resistant forms of nephrotic syndrome within an ethnic group can 
provide insight into potential biological mechanisms leading to disease. For example, 
among African-Americans, the risk variants in APOL1 are associated with a more than 
10-fold increase in risk of focal segmental glomerulosclerosis and high-risk carriers have 
a twofold greater risk of progression to end-stage renal disease. Ongoing collaborative 
studies should consider capturing data on self-reported ethnicity to understand differ-
ences in incidence and outcomes. In the future, the availability of whole-genome data will 
provide an excellent opportunity for new clinical and translational research in childhood 
nephrotic syndrome and lead to a better understanding of the disease.
Keywords: steroid resistant, steroid dependent, minimal change disease, focal segmental glomerulosclerosis, 
nephrotic syndrome
inTRODUCTiOn
Nephrotic syndrome is a common childhood kidney disease characterized by a constellation of heavy 
proteinuria (urine protein to creatinine ratio >200 mg/mmol or ≥3 + proteinuria on urine dipstick) 
resulting in hypoalbuminemia (<25 g/L), hyperlipidemia, and peripheral edema (1). Despite treating 
nephrotic syndrome with prednisone for over 50 years, the exact mechanism of disease remains 
unclear. Most studies focus on podocyte injury (2), immunological (3), and environmental factors 
(4) as potential culprits in the pathogenesis of nephrotic syndrome, but causal factors remain elusive.
Corticosteroids remain the mainstay for treatment of nephrotic syndrome. Based on the response 
to corticosteroids, children with nephrotic syndrome segregate into a steroid-sensitive group that 
has a good long-term prognosis, but risk of frequent relapses, and a steroid-resistant group with 
higher risk of developing chronic kidney disease. Response to medications is quite variable with 
some children requiring further courses of steroid-sparing agents, while others achieve complete 
remission after the first course of prednisone. Steroid-sparing agents, such as cyclophosphamide, 
mycophenolate mofetil, calcineurin inhibitors, and rituximab, are often used to induce or maintain 
remission with mixed results. It is unclear what leads to this individual variability in drug response 
and the future risk of relapses.
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Minimal change disease (MCD) is the most common histo-
logical variant of nephrotic syndrome and accounts for approxi-
mately 80% of cases in children based on historical data from 
1967 to 1976 (5). Focal segmental glomerulosclerosis (FSGS) is 
less common but can be progressive with poor long-term out-
comes. Data suggest differences in the incidence of FSGS among 
various ethnic groups, for example, a study involving 86 children 
from Kansas city, MO, USA, reported the annual incidence of 
FSGS of 1.6 per 100,000 in African-Americans compared to 0.3 
per 100,000 in European Americans (6).
With recent advancements and improved understanding of 
the human genome, 45 genes are found to be associated with 
familial and sporadic nephrotic syndrome that primarily affect 
podocyte structure and function (7). Most recently identified, 
the gene APOL1 is a major risk factor for FSGS among African-
Americans accounting for progressive kidney disease. The influ-
ence of genetic factors among other ethnic groups is less clear.
This review focuses on the current understanding of ethnic 
differences in childhood nephrotic syndrome, discusses ongoing 
studies and role of ethnicity, and the influence of genetics within 
specific ethnic groups.
eTHniC DiFFeRenCeS in nePHROTiC 
SYnDROMe
Based on our review of the literature, the average incidence of 
nephrotic syndrome is 4.7 (range 1.15–16.9) per 100,000 persons 
in studies reported from 1946 to 2014, and the proportion with 
steroid resistance is 12.4% (range 2.1–27.3%) from 1986 to 
2014 (Figures  1A,B). Hence, there is a considerable variation 
in disease burden by country of origin and steroid responsive-
ness, suggesting the potential role of ethnicity in susceptibility to 
disease (8–23).
In studies, where there are large diaspora populations, such as 
the United Kingdom, South Asians are reported to have a higher 
incidence of nephrotic syndrome ranging from 7.4 to 16.9 per 
100,000 persons compared to Europeans (14, 24, 25). Studies 
from the US report a higher estimated incidence among children 
of African compared to European descent (Figure 1A) (6, 13). 
The proportion of steroid resistance also varies by ethnicity 
from 20% among Europeans, 16–27% among Africans, 27–54% 
among Asians, and 20–39% among South Asians (Figure  1B) 
(26–29). It is possible that these differences are at least partially 
attributable to variations in clinical management, selection bias, 
and definitions of outcomes. African-American children are 
more likely to have biopsy-proven FSGS (42–72%) with worse 
outcomes as compared to European children and commonly 
progress to end-stage renal disease (ESRD) (19, 26, 27, 30–32). 
Comparatively, the proportion of FSGS in India ranges from 15.3 
to 39.1% (33, 34). All these reports have differing definitions, 
inconsistent inclusion, and selection criteria at tertiary centers 
and variable access to health care, which impact comparison of 
incidence rates and outcomes such as steroid responsiveness. In 
addition, most studies combine both steroid resistant and FSGS 
as a single category, thereby leading to further heterogeneity in 
study populations and impacting outcomes. On the other hand, 
registries from New Zealand and Netherlands did not show dif-
ferences in disease burden by ethnicity primarily due to lack of 
power or reported ethnic diversity (35, 36). These registries or 
case series have short follow-up and limited clinical information; 
hence, differences in treatment response by ethnicity are not well 
reported. To address these limitations, a number of ongoing reg-
istries and cohort studies conducted worldwide deserve mention. 
These studies include children with various types of nephrotic 
syndrome with the overall goal to identify clinical, histological 
and genomic predictors of nephrotic syndrome. The highlights 
of each study are shown in Table 1.
PodoNet is an international registry that includes children 
with steroid-resistant disease and congenital nephrotic syndrome 
recruited predominantly from European countries having 90.3% 
participants of European descent (37). Registry for Rare Kidney 
Diseases (RaDaR), recently renamed the National Study for 
Nephrotic Syndrome (NephroS) study, is a web-based UK regis-
try that aims to capture clinical information on all children and 
adults with nephrotic syndrome and studies to date have focused 
on genetic testing of steroid-resistant disease primarily involving 
Europeans (76.6%) (38).
Nephrotic Syndrome Study Network (NEPTUNE) and the 
Cure Glomerulonephropathy Network (CureGN) are both North 
American multicenter collaborative longitudinal cohort studies, 
which enroll both children and adults with biopsy-proven disease 
(MCD and FSGS). NEPTUNE recruits an incident cohort at the 
time of first biopsy and follows them closely for up to 5 years (39). 
It comprises a diverse ethnic cohort based on genetically derived 
ancestry. CureGN is a new multicenter study enrolling up to 2400 
children and adults with incident or prevalent MCD and FSGS. 
All of these studies to date have limited enrollment of either South 
Asians or East/Southeast Asians as many may not receive a biopsy 
or fulfill entry criteria, thus limiting their generalizability to other 
patient populations.
Canadian Childhood Nephrotic Syndrome (CHILDNEPH) is 
enrolling children across Canada to study treatment strategies in 
nephrotic syndrome and system factors driving treatment varia-
tion (40). Insight into Nephrotic Syndrome: Investigating Genes, 
Health, and Therapeutics (INSIGHT) is an ongoing longitudinal 
study, initially from Toronto, ON, Canada, that aims to detect 
factors that affect disease susceptibility and treatment response 
among children with nephrotic syndrome (41). The preliminary 
results from this study (42) demonstrate that South Asians have 
approximately 6 times higher incidence of nephrotic syndrome 
but significantly lower odds of frequently relapsing disease as 
compared to Europeans.
There is a clear geographical variation in the incidence of 
nephrotic syndrome. It is possible that the differences in inci-
dence by ethnicity are due to referral patterns at tertiary care 
centers or publication bias. The reason for variation in response 
to steroids and other immunosuppressive medications among 
specific ethnic groups has not been well documented. The results 
from registries and prospective studies will provide an excellent 
resource for future clinical and genetic research to understand 
disease pathogenesis and differences by ancestry.
A major limitation in understanding ethnic differences is the 
lack of detailed self-reported ethnicity data collected in most 
TABLe 1 | Distribution of ethnic groups in ongoing glomerular disease registries and prospective studies.
Study Participating 
centers
enrolled/
projected 
participants
initial start  
date
inclusion criteria ethnic groups
europeans 
(%)
South 
Asians (%)
east/South east 
Asians (%)
Others 
(%)
Registries
PodoNet (37) 67 1655 2009 Congenital/steroid-resistant nephrotic 
syndrome
90.3 0.9 0.4 8.4a
RaDaR (38) Not specified 220 2010 Children/adults with steroid-sensitive 
and -resistant nephrotic syndrome
76.6 2.6 0.06d 20c
Cohort studies
NEPTUNE (39) 18 450 2010 Children/adults with MCD, FSGS, 
and MN
48 – 9 44b
INSIGHT (41, 42) 2 450 2012 All children with nephrotic syndrome 24 33 10 33e
CureGN 64 2400 2014 Children/adults with MCD, FSGS, IgA 
nephropathy, and MN
Not available 
MCD, minimal change disease, FSGS, focal segmental glomerulosclerosis, MN, membranous nephropathy.
aIncludes Hispanic, mixed, and Native Americans.
bIncludes admixed Americans and Africans.
cIncludes North African, East African, Afro-Caribbean, mixed, and unknown.
dSpecified as “other Asian”.
eIncludes individuals classified as West Central Asian/Middle Eastern, West Indian/Caribbean and African, Latin/Central/South American and Aboriginal, multi-ethnic, and unknown.
FiGURe 1 | (A) Incidence of childhood nephrotic syndrome per 100,000 persons by ethnicity reported from 1946 to 2014. (B) Variability of steroid responsiveness 
by ethnicity among children with nephrotic syndrome in reported studies from 1986 to 2014.
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studies. Moreover, due to admixture it can be difficult to establish 
ethnicity among multi-ethnic children. Additionally, various 
cultural, environmental, and socioeconomic factors also act as 
important confounders and may influence individual variability 
to medication response and frequency of relapses. We provide 
a few suggestions for future studies in terms of collecting and 
reporting ethnicity data in children with nephrotic syndrome 
until genetic ancestry is available in some studies:
 1. Ethnicity should be self-reported;
 2. Ethnicity of two or more generations should be captured for 
multigenerational admixture;
 3. A uniform definition of ethnic groups should be used to 
compare across studies;
 4. Collaborative studies, both national and international, should 
include diverse ethnicities.
ROLe OF eTHniCiTY AnD GeneTiCS in 
CHiLDHOOD nePHROTiC SYnDROMe
There is an evolving role of genetic risk and development of 
nephrotic syndrome in children. The discovery of NPHS1 and 
NPHS2 genes leading to congenital nephrotic syndrome provided 
the first evidence of a genetic cause of steroid-resistant disease. 
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Since then, 45 genes have been associated with monogenic forms 
of nephrotic syndrome and highlight abnormalities in podocyte 
structure and function leading to disease (7). The current known 
genes associated with nephrotic syndrome account for only 
20–30% of hereditary and 10–20% of sporadic cases. The majority 
of these genes especially NPHS2 have been identified in European 
(43, 44), Japanese (45), and Turkish (46) families but have not 
been studied across broad ancestral groups where the allele 
frequency may vary and additional variants may be important. 
With advancement in genetic analyses, an increasing number of 
polymorphisms have been detected in children with nephrotic 
syndrome. It is important to note, however, that some variants are 
of unknown significance. It is difficult to determine whether these 
variants are common and/or pathogenic by ethnic or ancestral 
groups until genetic databases include more comprehensive 
information across many ethnic groups. Understanding the epide-
miological differences in kidney disease by ethnicity may suggest 
possible genetic risk. For example, African-Americans are known 
to have a 7.5% lifetime risk of reaching end-stage kidney disease, 
which is significantly higher than approximately 2% in European 
Americans (47). In 2008, studies using mapping admixture by 
linkage disequilibrium identified loci on chromosome 22 that 
explained the higher incidence of development of FSGS and ESRD 
among Africans Americans compared to European Americans. 
Initially, genetic risk was attributed to variants in the MYH9 
gene (48, 49). With new data available in the HapMAP, the major 
source of genetic risk for African-American non-diabetic ESRD 
and FSGS was localized to APOL1, encoding apolipoprotein 
L1 (ApoL1), which is only 14 kb from the gene MYH9 (50, 51). 
Risk of advanced kidney disease is two to seven times greater for 
those carrying risk alleles of APOL1, as compared to controls. The 
spectrum of APOL1-associated kidney disease is quite diverse 
and includes nephrotic syndrome (FSGS), non-diabetic chronic 
kidney disease secondary to hypertension, HIV-associated col-
lapsing glomerulopathy (52), sickle cell nephropathy (53), and 
lupus nephritis (54). A recent study also demonstrated that the 
risk of progression of chronic kidney disease is approximately 
two times higher in African-Americans with APOL1 variants 
despite adequate blood pressure control (55). Interestingly, some 
individuals carrying APOL1 risk alleles do not develop kidney 
disease highlighting the role of additional genetic or environ-
mental interactions (56). To further understand the association 
of APOL1 variants with different rates of chronic kidney disease 
across various African countries and potential environmental 
interaction, the Kidney Disease Network of Human Hereditary 
and Health in Africa (H3Africa) consortium was established (57).
Recently, a study among 214 children with steroid-sensitive 
nephrotic syndrome from South Asia, specifically Sri Lanka, 
reported HLA-DQA1 missense coding variants as possible can-
didate loci based on exome array in case–control study compared 
to 149 healthy controls. The study findings were then confirmed 
among a replication sample of 100 European children with 
steroid-sensitive nephrotic syndrome and 205 European controls. 
This study supports the contributory role of immune response in 
the pathogenesis of nephrotic syndrome (58) and will need to be 
tested in additional cohorts with diverse ethnic groups. Previous 
smaller studies in Chinese and Japanese children have also 
reported association between variants in HLA-DQ3, HLA-DQ8, 
HLA-DR, HLADQW2, HLA-DQA1, and HLA-DQB1 in 
nephrotic syndrome (59–62).
eTHniC DiFFeRenCeS in OTHeR 
GLOMeRULAR DiSeASeS
In specific ethnic groups, genome-wide association studies have 
identified susceptibility loci for membranous and IgA nephropa-
thies. HLA-DQA1 allele on chromosome 6p21 is most closely 
associated with idiopathic membranous nephropathy in persons 
of European ancestry (63). IgA nephropathy, the most common 
cause of glomerulonephritis in adults, has a higher prevalence 
in Asians as compared to North-Americans or Europeans (64). 
Recently, in a large diverse cohort of patients with IgA nephropa-
thy, individuals with Pacific Asian origin were shown to have 
a higher risk of progression to ESRD (65). Studies among East 
Asians with IgA nephropathy have identified susceptibility loci 
with the strongest association in the region that include the HLA-
DRB1, -DQA1, and -DQB1 genes (66). Similar studies are quite 
scarce in children with nephrotic syndrome.
COnCLUSiOn
In children with nephrotic syndrome, incidence and response to 
treatment varies by ethnicity. It is likely that genetic and envi-
ronmental risk factors play a substantial role in explaining these 
ethnic differences and need further study.
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